AstraZeneca selects new heart failure target with BenevolentAI
The target was discovered leveraging the AI-driven drug discovery platform of BenevolentAI and validated by AstraZeneca.
Stay updated with breaking news from Benevolent Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The target was discovered leveraging the AI-driven drug discovery platform of BenevolentAI and validated by AstraZeneca.
Regulatory News: BenevolentAI , a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of...
BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers London, UK, 25 March...
AI provider BenevolentAI has announced the appointment of Dr. Click to read more...
Regulatory News: Posted to shareholders on 27 December 2023 Dear Shareholders AI is becoming an accepted and validated approach to drug discovery and development with long term structural...